Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal Reduction: Health Status Analysis Through Week 56 in VALOR-HCM Trial.

Authors

Milind Y Desai
Anjali Owens
Kathy Wolski
Jeffrey B Geske
Sara Saberi
Andrew Wang
Mark Sherrid
Paul C Cremer
Neal K Lakdawala
David Fermin, Corewell Health West

Document Type

Article

Publication Date

9-10-2024

Publication Title

Journal of the American College of Cardiology

Volume

84

Issue

11

First Page

1041

Last Page

1045

Recommended Citation

Desai MY, Owens A, Wolski K, Geske JB, Saberi S, Wang A, et al [Fermin D] Mavacamten in obstructive hypertrophic cardiomyopathy patients referred for septal reduction: health status analysis through week 56 in valor-hcm trial. J Am Coll Cardiol. 2024 Sep 10;84(11):1041-1045. doi: 10.1016/j.jacc.2024.06.025. PMID: 39232631

DOI

10.1016/j.jacc.2024.06.025

ISSN

1558-3597

PubMed ID

39232631